{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T16:51:55Z","timestamp":1775580715809,"version":"3.50.1"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,8,21]],"date-time":"2019-08-21T00:00:00Z","timestamp":1566345600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,8,21]],"date-time":"2019-08-21T00:00:00Z","timestamp":1566345600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Cryptosporidiosis is a major cause of diarrheal disease. The only drug approved for cryptosporidiosis has limited efficacy in high-risk populations. Therefore novel drugs are urgently needed. We have identified several enzymes as potential targets for drug development and we have optimized a rapid method to silence genes in <jats:italic>Cryptosporidium<\/jats:italic>. In this study, we knocked down expression of the four selected genes: Actin (Act), Apicomplexan DNA-binding protein (Ap2), Rhomboid protein 1 (Rom 1), and nucleoside diphosphate kinase (NDK). After gene silencing, we evaluated the role of each target on parasite development using <jats:italic>in vitro<\/jats:italic> models of excystation, invasion, proliferation, and egress. We showed that silencing of Act, Ap2, NDK, and Rom1 reduced invasion, proliferation, and egress of <jats:italic>Cryptosporidium<\/jats:italic>. However, silencing of NDK markedly inhibited <jats:italic>Cryptosporidium<\/jats:italic> proliferation (~70%). We used an infection model to evaluate the anticryptosporidial activity of ellagic acid (EA), an NDK inhibitor. We showed that EA (EC50\u2009=\u200915\u201330\u2009\u00b5M) reduced parasite burden without showing human cell toxicity. Here, we demonstrated the usefulness of a rapid silencing method to identify novel targets for drug development. Because EA is a dietary supplement already approved for human use, this compound should be studied as a potential treatment for cryptosporidiosis.<\/jats:p>","DOI":"10.1038\/s41598-019-48544-z","type":"journal-article","created":{"date-parts":[[2019,8,21]],"date-time":"2019-08-21T10:02:54Z","timestamp":1566381774000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Systematic gene silencing identified Cryptosporidium nucleoside diphosphate kinase and other molecules as targets for suppression of parasite proliferation in human intestinal cells"],"prefix":"10.1038","volume":"9","author":[{"given":"A.","family":"Castellanos-Gonzalez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Martinez-Traverso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Fishbeck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Nava","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"Jr","given":"A. C.","family":"White","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,8,21]]},"reference":[{"key":"48544_CR1","doi-asserted-by":"publisher","first-page":"e758","DOI":"10.1016\/S2214-109X(18)30283-3","volume":"6","author":"IA Khalil","year":"2018","unstructured":"Khalil, I. A. et al. Morbidity, mortality, and long-term consequences associated with diarrhoea from Cryptosporidium infection in children younger than 5 years: a meta-analyses study. Lancet. Glob Health 6, e758\u2013e768, https:\/\/doi.org\/10.1016\/S2214-109X(18)30283-3 (2018).","journal-title":"Glob Health"},{"key":"48544_CR2","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/s40475-015-0056-9","volume":"2","author":"H Sparks","year":"2015","unstructured":"Sparks, H., Nair, G., Castellanos-Gonzalez, A. & White, A. C. Jr. Treatment of Cryptosporidium: What We Know, Gaps, and the Way Forward. Curr Trop Med Rep 2, 181\u2013187, https:\/\/doi.org\/10.1007\/s40475-015-0056-9 (2015).","journal-title":"Curr Trop Med Rep"},{"key":"48544_CR3","doi-asserted-by":"publisher","first-page":"e0003987","DOI":"10.1371\/journal.pntd.0003987","volume":"9","author":"CD Huston","year":"2015","unstructured":"Huston, C. D. et al. A Proposed Target Product Profile and Developmental Cascade for New Cryptosporidiosis Treatments. PLoS Negl Trop Dis 9, e0003987, https:\/\/doi.org\/10.1371\/journal.pntd.0003987 (2015).","journal-title":"PLoS Negl Trop Dis"},{"key":"48544_CR4","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/S1473-3099(14)70772-8","volume":"15","author":"W Checkley","year":"2015","unstructured":"Checkley, W. et al. A review of the global burden, novel diagnostics, therapeutics, and vaccine targets for cryptosporidium. Lancet Infect Dis 15, 85\u201394, https:\/\/doi.org\/10.1016\/S1473-3099(14)70772-8 (2015).","journal-title":"Lancet Infect Dis"},{"key":"48544_CR5","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1093\/infdis\/jiv588","volume":"213","author":"A Castellanos-Gonzalez","year":"2016","unstructured":"Castellanos-Gonzalez, A., Perry, N., Nava, S. & White, A. C. Jr. Preassembled Single-Stranded RNA-Argonaute Complexes: A Novel Method to Silence Genes in Cryptosporidium. The Journal of infectious diseases 213, 1307\u20131314, https:\/\/doi.org\/10.1093\/infdis\/jiv588 (2016).","journal-title":"The Journal of infectious diseases"},{"key":"48544_CR6","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1038\/nsmb918","volume":"12","author":"FV Rivas","year":"2005","unstructured":"Rivas, F. V. et al. Purified Argonaute2 and an siRNA form recombinant human RISC. Nature structural & molecular biology 12, 340\u2013349, https:\/\/doi.org\/10.1038\/nsmb918 (2005).","journal-title":"Nature structural & molecular biology"},{"key":"48544_CR7","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1006\/meth.2001.1262","volume":"25","author":"KJ Livak","year":"2001","unstructured":"Livak, K. J. & Schmittgen, T. D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(\u2212Delta Delta C(T)) Method. Methods 25, 402\u2013408, https:\/\/doi.org\/10.1006\/meth.2001.1262 (2001).","journal-title":"Methods"},{"key":"48544_CR8","doi-asserted-by":"publisher","unstructured":"Nava, S., White, A. C., Jr. & Castellanos-Gonzalez, A. Cryptosporidium parvum Subtilisin-Like Serine Protease (SUB1) Is Crucial for Parasite Egress from Host Cells. Infection and immunity 87, https:\/\/doi.org\/10.1128\/IAI.00784-18 (2019).","DOI":"10.1128\/IAI.00784-18"},{"key":"48544_CR9","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1126\/science.1094786","volume":"304","author":"MS Abrahamsen","year":"2004","unstructured":"Abrahamsen, M. S. et al. Complete genome sequence of the apicomplexan, Cryptosporidium parvum. Science 304, 441\u2013445, https:\/\/doi.org\/10.1126\/science.1094786 (2004).","journal-title":"Science"},{"key":"48544_CR10","doi-asserted-by":"publisher","first-page":"5379","DOI":"10.1128\/IAI.73.9.5379-5387.2005","volume":"73","author":"DM Wetzel","year":"2005","unstructured":"Wetzel, D. M., Schmidt, J., Kuhlenschmidt, M. S., Dubey, J. P. & Sibley, L. D. Gliding motility leads to active cellular invasion by Cryptosporidium parvum sporozoites. Infection and immunity 73, 5379\u20135387, https:\/\/doi.org\/10.1128\/IAI.73.9.5379-5387.2005 (2005).","journal-title":"Infection and immunity"},{"key":"48544_CR11","doi-asserted-by":"publisher","first-page":"7922","DOI":"10.1128\/JB.00461-07","volume":"189","author":"B Weiss","year":"2007","unstructured":"Weiss, B. The deoxycytidine pathway for thymidylate synthesis in Escherichia coli. J Bacteriol 189, 7922\u20137926, https:\/\/doi.org\/10.1128\/JB.00461-07 (2007).","journal-title":"J Bacteriol"},{"key":"48544_CR12","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1016\/j.copbio.2010.05.009","volume":"21","author":"LD Sibley","year":"2010","unstructured":"Sibley, L. D. How apicomplexan parasites move in and out of cells. Curr Opin Biotechnol 21, 592\u2013598, https:\/\/doi.org\/10.1016\/j.copbio.2010.05.009 (2010).","journal-title":"Curr Opin Biotechnol"},{"key":"48544_CR13","doi-asserted-by":"publisher","first-page":"e31715","DOI":"10.1371\/journal.pone.0031715","volume":"7","author":"MJ Mauzy","year":"2012","unstructured":"Mauzy, M. J., Enomoto, S., Lancto, C. A., Abrahamsen, M. S. & Rutherford, M. S. The Cryptosporidium parvum transcriptome during in vitro development. PloS one 7, e31715, https:\/\/doi.org\/10.1371\/journal.pone.0031715 (2012).","journal-title":"PloS one"},{"key":"48544_CR14","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1038\/nmeth812","volume":"2","author":"HF Zhao","year":"2005","unstructured":"Zhao, H. F. et al. High-throughput screening of effective siRNAs from RNAi libraries delivered via bacterial invasion. Nat Methods 2, 967\u2013973, https:\/\/doi.org\/10.1038\/nmeth812 (2005).","journal-title":"Nat Methods"},{"key":"48544_CR15","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1016\/S0092-8674(00)81071-5","volume":"84","author":"JM Dobrowolski","year":"1996","unstructured":"Dobrowolski, J. M. & Sibley, L. D. Toxoplasma invasion of mammalian cells is powered by the actin cytoskeleton of the parasite. Cell 84, 933\u2013939 (1996).","journal-title":"Cell"},{"key":"48544_CR16","doi-asserted-by":"publisher","first-page":"e1000784","DOI":"10.1371\/journal.ppat.1000784","volume":"6","author":"C Flueck","year":"2010","unstructured":"Flueck, C. et al. A major role for the Plasmodium falciparum ApiAP2 protein PfSIP2 in chromosome end biology. PLoS pathogens 6, e1000784, https:\/\/doi.org\/10.1371\/journal.ppat.1000784 (2010).","journal-title":"PLoS pathogens"},{"key":"48544_CR17","doi-asserted-by":"publisher","first-page":"6871","DOI":"10.1073\/pnas.1300059110","volume":"110","author":"JB Radke","year":"2013","unstructured":"Radke, J. B. et al. ApiAP2 transcription factor restricts development of the Toxoplasma tissue cyst. Proceedings of the National Academy of Sciences of the United States of America 110, 6871\u20136876, https:\/\/doi.org\/10.1073\/pnas.1300059110 (2013).","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"48544_CR18","doi-asserted-by":"publisher","first-page":"6057","DOI":"10.1093\/nar\/gky373","volume":"46","author":"KM Lesage","year":"2018","unstructured":"Lesage, K. M. et al. Cooperative binding of ApiAP2 transcription factors is crucial for the expression of virulence genes in Toxoplasma gondii. Nucleic acids research 46, 6057\u20136068, https:\/\/doi.org\/10.1093\/nar\/gky373 (2018).","journal-title":"Nucleic acids research"},{"key":"48544_CR19","doi-asserted-by":"publisher","unstructured":"Huang, S. et al. Toxoplasma gondii AP2IX-4 Regulates Gene Expression during Bradyzoite Development. mSphere 2, https:\/\/doi.org\/10.1128\/mSphere.00054-17 (2017).","DOI":"10.1128\/mSphere.00054-17"},{"key":"48544_CR20","doi-asserted-by":"publisher","first-page":"e1007035","DOI":"10.1371\/journal.ppat.1007035","volume":"14","author":"JB Radke","year":"2018","unstructured":"Radke, J. B. et al. Transcriptional repression by ApiAP2 factors is central to chronic toxoplasmosis. PLoS pathogens 14, e1007035, https:\/\/doi.org\/10.1371\/journal.ppat.1007035 (2018).","journal-title":"PLoS pathogens"},{"key":"48544_CR21","doi-asserted-by":"publisher","first-page":"20043","DOI":"10.1073\/pnas.0709999104","volume":"104","author":"S Singh","year":"2007","unstructured":"Singh, S., Plassmeyer, M., Gaur, D. & Miller, L. H. Mononeme: a new secretory organelle in Plasmodium falciparum merozoites identified by localization of rhomboid-1 protease. Proceedings of the National Academy of Sciences of the United States of America 104, 20043\u201320048, https:\/\/doi.org\/10.1073\/pnas.0709999104 (2007).","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"48544_CR22","first-page":"30","volume":"51","author":"IL Buxton","year":"2008","unstructured":"Buxton, I. L. Inhibition of Nm23H2 gene product (NDPK-B) by angiostatin, polyphenols and nucleoside analogs. Proc West Pharmacol Soc 51, 30\u201334 (2008).","journal-title":"Proc West Pharmacol Soc"},{"key":"48544_CR23","first-page":"57","volume":"44","author":"NA Malmquist","year":"2001","unstructured":"Malmquist, N. A., Anzinger, J. J., Hirzel, D. & Buxton, I. L. Ellagic acid inhibits nucleoside diphosphate kinase-B activity. Proc West Pharmacol Soc 44, 57\u201359 (2001).","journal-title":"Proc West Pharmacol Soc"},{"key":"48544_CR24","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1128\/AAC.01175-08","volume":"53","author":"PN Soh","year":"2009","unstructured":"Soh, P. N. et al. In vitro and in vivo properties of ellagic acid in malaria treatment. Antimicrobial agents and chemotherapy 53, 1100\u20131106, https:\/\/doi.org\/10.1128\/AAC.01175-08 (2009).","journal-title":"Antimicrobial agents and chemotherapy"},{"issue":"11","key":"48544_CR25","doi-asserted-by":"publisher","first-page":"1756","DOI":"10.3390\/nu10111756","volume":"10","author":"Claudia Ceci","year":"2018","unstructured":"Ceci, C. et al. Experimental Evidence of the Antitumor, Antimetastatic and Antiangiogenic Activity of Ellagic Acid. Nutrients 10, https:\/\/doi.org\/10.3390\/nu10111756 (2018).","journal-title":"Nutrients"},{"key":"48544_CR26","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1093\/jac\/dky079","volume":"73","author":"R De","year":"2018","unstructured":"De, R. et al. Antimicrobial activity of ellagic acid against Helicobacter pylori isolates from India and during infections in mice. J Antimicrob Chemother 73, 1595\u20131603, https:\/\/doi.org\/10.1093\/jac\/dky079 (2018).","journal-title":"J Antimicrob Chemother"},{"key":"48544_CR27","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1038\/bjc.2017.301","volume":"117","author":"N Gurvits","year":"2017","unstructured":"Gurvits, N. et al. Separase is a marker for prognosis and mitotic activity in breast cancer. Br J Cancer 117, 1383\u20131391, https:\/\/doi.org\/10.1038\/bjc.2017.301 (2017).","journal-title":"Br J Cancer"},{"key":"48544_CR28","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1111\/jop.12223","volume":"44","author":"A Promsong","year":"2015","unstructured":"Promsong, A., Chung, W. O., Satthakarn, S. & Nittayananta, W. Ellagic acid modulates the expression of oral innate immune mediators: potential role in mucosal protection. J Oral Pathol Med 44, 214\u2013221, https:\/\/doi.org\/10.1111\/jop.12223 (2015).","journal-title":"J Oral Pathol Med"},{"key":"48544_CR29","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1016\/j.jep.2013.09.030","volume":"150","author":"M Marin","year":"2013","unstructured":"Marin, M., Maria Giner, R., Rios, J. L. & Recio, M. C. Intestinal anti-inflammatory activity of ellagic acid in the acute and chronic dextrane sulfate sodium models of mice colitis. J Ethnopharmacol 150, 925\u2013934, https:\/\/doi.org\/10.1016\/j.jep.2013.09.030 (2013).","journal-title":"J Ethnopharmacol"},{"issue":"7","key":"48544_CR30","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1002\/tox.22747","volume":"34","author":"Yasmeen Goyal","year":"2019","unstructured":"Goyal, Y., Koul, A. & Ranawat, P. Ellagic acid ameliorates cisplatin induced hepatotoxicity in colon carcinogenesis. Environ Toxicol, https:\/\/doi.org\/10.1002\/tox.22747 (2019).","journal-title":"Environmental Toxicology"},{"key":"48544_CR31","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1139\/apnm-2017-0583","volume":"43","author":"Y Liu","year":"2018","unstructured":"Liu, Y. et al. Chronic administration of ellagic acid improved the cognition in middle-aged overweight men. Appl Physiol Nutr Metab 43, 266\u2013273, https:\/\/doi.org\/10.1139\/apnm-2017-0583 (2018).","journal-title":"Appl Physiol Nutr Metab"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-48544-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-48544-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-48544-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,17]],"date-time":"2022-12-17T12:50:43Z","timestamp":1671281443000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-48544-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,21]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,12]]}},"alternative-id":["48544"],"URL":"https:\/\/doi.org\/10.1038\/s41598-019-48544-z","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,21]]},"assertion":[{"value":"31 May 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 August 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"12153"}}